이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Medulloblastoma에 대한 Cranial-Spinal Radiation을 가진 어린이의 뇌 복구를 위한 Metformin

2026년 9월 21일 업데이트: Donald Mabbott, The Hospital for Sick Children

수모세포종에 대한 두개골-척수 방사선을 가진 소아의 뇌 복구를 위한 메트포르민의 위약 대조 이중 맹검 교차 시험

A placebo controlled double blind crossover trial of metformin in 30 children treated with radiation for medulloblastoma - the most common malignant brain tumour. The investigators used tests of thinking and learning and brain imaging techniques to examine whether metformin can enhance cognition or promote brain repair following radiation-induced brain injury.

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

We conducted a pilot randomized, double-blind, placebo-controlled trial with crossover in survivors of pediatric brain tumors with primary endpoints of safety and feasibility and secondary endpoints of cognitive and magnetic resonance imaging (MRI) measures. Twenty-four participants were enrolled and randomly assigned to complete 12-week cycles of metformin (A) and placebo (B) in either a group AB (AB) or group BA (BA) sequence. At the point of crossover, there was a 10-week washout period in which neither group received any treatment. During the first week of each treatment cycle, a daily dose of 500 mg/m2 of metformin or placebo was administered orally. The dose was increased to 1000mg/m2 daily beginning in the second week and continuing for the remainder of the 12-week cycle.

Test procedures (Clinical & current medications reviews, Blood draws, and MRI and Cognitive testing) were performed at 4 times points during the study: 1. at study entry (Baseline 1), 2. after 12 weeks of treatment (Outcome 1), 3. after a 10-week washout period at 22 weeks (Baseline 2), and 4. At the end of the trial at 34 weeks (Outcome 2).

연구 유형

중재적

등록 (실제)

24

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Ontario
      • Toronto, Ontario, 캐나다, M5G 1X8
        • The Hospital for Sick Children

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

5년 (어린이, 성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion criteria: Survivors will be included if they:

  1. Have been treated with cranial or cranial-spinal radiation,

  2. Are between 5 and 21 years of age at time of consent, and

  3. Either declare English as their native language or have had at least two years of schooling in English at the time of their baseline assessment.

  4. Have been diagnosed with a brain tumour requiring treatment with cranial or cranial-spinal radiation at least 2 years ago, is not receiving active treatment and no more than 15 years may have elapsed between treatment with cranial-spinal radiation and time of the trial. Survivors with a shunt will be included in the trial, but will need to be identified prior to study enrollment to discuss any specific considerations for imaging.

  5. Meet criteria for adequate organ function requirements:

    1. Adequate renal function defined as: Creatinine clearance or radioisotope glomerular filtration rate (GFR) > 70ml/min/1.73 m2 or serum creatinine based on age/gender as follows:

      Maximum Serum Creatinine Level (mg/dL)

      5 to < 10 years: Male = 1; Female = 1

      10 to < 13 years: Male = 1.2; Female = 1.2

      13 to < 16 years: Male = 1.5; Female = 1.4

      ≥ 16 years: Male = 1.7; Female = 1.4

    2. Adequate liver function defined as:

    Total bilirubin < 1.5 x upper limit of normal (ULN) for age, and,

    serum glutamate oxaloacetate transaminase (SGOT) (AST) or serum glutamate pyruvate transaminase (SGPT) (ALT) < 3 x upper limit of normal (ULN) for age.

  6. Females of childbearing potential must have a negative pregnancy test result and must agree to use a medically acceptable method of contraception throughout the entire study period and for 30 days after the last dose of study drug.

  7. Informed consent will be obtained from the participants and/or their legal guardians by study team members authorized to consent for this study.

Exclusion criteria: Survivors will be excluded if they

  1. Are receiving palliative care.
  2. Are unable to participate in neuro-imaging without sedation as this is the primary outcome measure for the trial.
  3. Are unable to swallow tablets.
  4. Are unstable and/or insulin-dependent (Type 1) diabetic patients.
  5. Have acute or chronic metabolic acidosis and/or lactic acidosis.
  6. Any female patient or partner who has reached menarche and male patients who are not willing to use an effective method of contraception.
  7. Patient who is pregnant or lactating and does not agree to stop breastfeeding while receiving trial treatment.
  8. Have a history of renal disease or renal dysfunction e.g., as suggested by elevated serum creatinine levels (see 5.a. Inclusion criteria) or abnormal creatinine clearance.
  9. Have a history of congestive heart failure requiring pharmacologic treatment.
  10. Have a known hypersensitivity to metformin hydrochloride.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Group A (Crossover Group 1)

Subjects assigned to this arm will receive metformin first, followed by a washout period and then placebo.

Metformin doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.

Placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.

실험적: Group B (Crossover Group 2)

Subjects assigned to this arm will receive placebo first, followed by a washout period and then metformin.

Metformin doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.

Placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Feasibility: Medication Adherence
기간: Outcome 2 (Week 35)

Participant's adherence to taking study medication (Metformin or Placebo) as instructed based on dosing nomogram, for the whole study.

% Medication adherence = (Number of tablets actually consumed / Number of tablets expected to be consumed)*100

Number of tablets actually consumed is based on compliance counts conducted at the end of the study.

Outcome 2 (Week 35)
Safety: Frequency of Adverse Events (AE)
기간: Outcome 2 (Week 35)

The frequency of all AEs experienced during metformin and placebo treatment for all participants.

Outcome 2 (Week 35)

2차 결과 측정

결과 측정
측정값 설명
기간
Cognitive Testing: Declarative Memory - Change in Children's Auditory Verbal Learning Test -2 (CAVLT-2)
기간: Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)

For Arm AB:

  1. Change in Immediate Recall test from Baseline 1 (Week 1) at Outcome 1 (Week 13, post 12-week intervention)
  2. Change in Immediate Recall test from Baseline 2 (Week 23, post 10-week washout) at Outcome 2 (Week 35, post 2nd 12-week intervention)
  3. Change in Immediate Recall test from Baseline 1 (Week 1) at Outcome 2 (Week 35, post 2nd 12-week intervention)

For Arm BA:

  1. Change in Immediate Recall test from Baseline 1 (Week 1) at Outcome 1 (Week 13)
  2. Change in Immediate Recall test from Baseline 2 (Week 23) at Outcome 2 (Week 35)
  3. Change in Immediate Recall test from Baseline 1 (Week 1) at Outcome 2 (Week 35)
Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)
Cognitive Testing: Working Memory - Change in List Sort Working Memory Subtest of the NIH Toolbox Cognition Battery
기간: Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), Outcome 2 (Week 35)

For Arm AB:

  1. Change in List Sort Working Memory Test from Baseline 1 (Week 1) at Outcome 1 (Week 13)
  2. Change in List Sort Working Memory Test from Baseline 2 (Week 23) at Outcome 2 (Week 35)
  3. Change in List Sort Working Memory Test from Baseline 1 (Week 1) at Outcome 2 (Week 35)

For Arm BA:

  1. Change in List Sort Working Memory Test from Baseline 1 (Week 1) at Outcome 1 (Week 13)
  2. Change in List Sort Working Memory Test from Baseline 2 (Week 23) at Outcome 2 (Week 35)
  3. Change in List Sort Working Memory Test from Baseline 1 (Week 1) at Outcome 2 (Week 35)
Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), Outcome 2 (Week 35)
Cognitive Testing: Processing Speed - Change in Mean Reaction Time across Cambridge Neuropsychological Test Automated Battery (CANTAB) subtests
기간: Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)

Change in Mean Reaction Time (MRT) across the following CANTAB subtests:

  1. Rapid Visual Information Processing (RVP)
  2. Reaction Time (RT)
  3. Match to Sample Visual Search (MTS)
  4. Delayed Matching in sample (DMS)

Each subtest provides an outcome measure of response latency, which will be averaged across all correct trials for each subtest to provide an overall measure of processing speed.

For Arm AB:

  1. Change in MRT from Baseline 1 (Week 1) at Outcome 1 (Week 13)
  2. Change in MRT from Baseline 2 (Week 23) at Outcome 2 (Week 35)
  3. Change in MRT from Baseline 1 (Week 1) at Outcome 2 (Week 35)

For Arm BA:

  1. Change in MRT from Baseline 1 (Week 1) at Outcome 1 (Week 13)
  2. Change in MRT from Baseline 2 (Week 23) at Outcome 2 (Week 35)
  3. Change in MRT from Baseline 1 (Week 1) at Outcome 2 (Week 35)
Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)

기타 결과 측정

결과 측정
측정값 설명
기간
Neuroimaging: MRI Measures of White Matter Growth within the Corpus Callosum
기간: Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)

Change in Axonal Water Fraction (AWF)- Diffusion Kurtosis Imaging (DKI) metric sensitive to myelin

Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)
Neuroimaging: MRI Measures of Hippocampal Volume
기간: Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35

Change in Hippocampal Volume, as measured by Cerebral Blood Flow (CBF)

Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Donald Mabbott, PhD, The Hospital for Sick Children

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2014년 6월 13일

기본 완료 (실제)

2017년 12월 15일

연구 완료 (실제)

2017년 12월 15일

연구 등록 날짜

최초 제출

2014년 1월 7일

QC 기준을 충족하는 최초 제출

2014년 1월 15일

처음 게시됨 (추정된)

2014년 1월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 24일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 21일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 1000039383

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .